Tagged with Qiagen

MEA For decades, the Middle East has faced a disproportionately high burden of rare genetic disorders, fuelled both by deep-rooted cultural practices and an overreliance on Western genomic data. Fast forward to 2026, and massive genome projects across the Gulf region are attempting to shift the narrative. Backed by immense sovereign…

MEA Hussein Abhari, Head of the MENA region, QIAGEN, has led the company’s regional presence since 2017, spanning products for molecular research and clinical testing. His priorities focus on strengthening long-term partnerships, supporting national healthcare strategies, building local scientific capacity and ensuring advanced molecular and genetic technologies translate into real-world clinical…

USA Precision medicine increasingly depends on diagnostics that can keep pace with therapeutic innovation while remaining accessible in real-world care. Jonathan Arnold reflects on how QIAGEN approaches oncology and emerging hereditary disease programmes by aligning diagnostic development with pharmaceutical pipelines, prioritising decentralisation, and investing in technologies that support both translational insight…

Switzerland QIAGEN’s Sample Technologies portfolio sits at the core of the company’s mission to deliver the highest-quality products to enable valuable molecular insights to more than 500,000 customers across life sciences and clinical diagnostics. Under the leadership of Michael Scheffler, Vice President and Head of Global Sample Technologies, this portfolio continues…

Saudi Arabia Simona Grandits, VP of EEMEA at QIAGEN, reflects on the evolution of the German company whose revenues are now split between life sciences and molecular diagnostics, and the growing importance of bioinformatics for which QIAGEN is developing a data centre in Saudi Arabia. Grandits also reviews QIAGEN’s preventive healthcare initiatives…